191 related articles for article (PubMed ID: 38670592)
21. Whole genome sequencing of matched tumor, adjacent non-tumor tissues and corresponding normal blood samples of hepatocellular carcinoma patients revealed dynamic changes of the mutations profiles during hepatocarcinogenesis.
Mao R; Liu J; Liu G; Jin S; Xue Q; Ma L; Fu Y; Zhao N; Xing J; Li L; Qiu Y; Lin B
Oncotarget; 2017 Apr; 8(16):26185-26199. PubMed ID: 28412734
[TBL] [Abstract][Full Text] [Related]
22. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
[TBL] [Abstract][Full Text] [Related]
23. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence.
Zhou SL; Zhou ZJ; Hu ZQ; Song CL; Luo YJ; Luo CB; Xin HY; Yang XR; Shi YH; Wang Z; Huang XW; Cao Y; Fan J; Zhou J
J Hepatol; 2019 Dec; 71(6):1152-1163. PubMed ID: 31349001
[TBL] [Abstract][Full Text] [Related]
24. Genomic structures of dysplastic nodule and concurrent hepatocellular carcinoma.
Lee M; Kim K; Kim SY; Jung SH; Yoon J; Kim MS; Park HC; Jung ES; Chung YJ; Lee SH
Hum Pathol; 2018 Nov; 81():37-46. PubMed ID: 29949741
[TBL] [Abstract][Full Text] [Related]
25. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
[TBL] [Abstract][Full Text] [Related]
26. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
[TBL] [Abstract][Full Text] [Related]
28. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
[TBL] [Abstract][Full Text] [Related]
29. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
30. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
31. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
32. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
33. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
[TBL] [Abstract][Full Text] [Related]
34. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
[TBL] [Abstract][Full Text] [Related]
35. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
Li S; Mao M
Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663
[TBL] [Abstract][Full Text] [Related]
36. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
37. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
38. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
Lin J; Shi J; Guo H; Yang X; Jiang Y; Long J; Bai Y; Wang D; Yang X; Wan X; Zhang L; Pan J; Hu K; Guan M; Huo L; Sang X; Wang K; Zhao H
Clin Cancer Res; 2019 Aug; 25(15):4701-4711. PubMed ID: 31068370
[TBL] [Abstract][Full Text] [Related]
39. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Yamamoto Y; Ashida R; Ohgi K; Nagashima T; Yamaguchi K
J Hepatobiliary Pancreat Sci; 2023 Mar; 30(3):269-282. PubMed ID: 35918906
[TBL] [Abstract][Full Text] [Related]
40. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]